# US 2019/0375839 A1 · Tim-3 antibody, antigen binding fragment thereof, and medicinal uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375839 A1
- Document ID: US20190375839A1
- Status: Published application
- Kind: A1
- Application number: 16/487,321
- Filed: 2018-02-26
- Published: 2019-12-12
- Earliest claimed: 2017-02-27
- Assignees: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Applicants: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Inventors: Zhuoxiao CAO; Yayuan FU; Ting ZHANG; Weikang TAO
- Web page: https://patentgrep.com/patent/US20190375839A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/567: Framework region [FR]
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2333/4725: Mucins, e.g. human intestinal mucin
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A TIM-3 antibody, an antigen-binding fragment thereof, and medical uses thereof are described. More specifically, the present invention provides a rat-derived antibody containing a CDR region of the TIM-3 antibody, a chimeric antibody or a human-derived antibody thereof, and a pharmaceutical composition containing the TIM-3 antibody and the antigen-binding fragment thereof, as well as uses thereof serving as a drug. In particular, the present invention provides uses of a human-derived TIM-3 antibody in the preparation of drugs for treating TIM-3 -related conditions.

## Claims

### Claim 1

A TIM-3 antibody or antigen-binding fragment thereof which binds to an extracellular region of human TIM-3 antigen and is selected from any one of the monoclonal antibody or antigen-binding fragment thereof of the following (i) to (ii):
(i) a monoclonal antibody or antigen-binding fragment thereof, comprising
heavy chain variable region HCDR 1-3 sequences as shown in: SEQ ID NOs: 8, 43 and 10, respectively; and light chain variable region LCDR 1-3 sequences as shown in: SEQ ID NOs: 11, 12 and 13, respectively,
wherein the SEQ ID NO: 43 is shown as DIIPX1X2X3GSKYNQKFKD,
wherein X1 is N, L, V, M or E, X2 is N, E, M, H, K, L, A or V; and X3 is G or A; or
(ii) a monoclonal antibody or antigen-binding fragment thereof, comprising
heavy chain variable region HCDR 1-3 sequences as shown in: SEQ ID NOs: 14, 15 and 16 respectively; and light chain variable region LCDR 1-3 sequences as shown in: SEQ ID NOs: 17, 18 and 19, respectively,
or a monoclonal antibody or antigen-binding fragment thereof that competes with the monoclonal antibody or antigen-binding fragment of (i) or (ii).

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 1, selected from any one of the monoclonal antibody or antigen-binding fragment thereof of the following (a) to (m):
(a) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 9 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(b) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 62 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(c) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 63 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(d) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 64 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(e) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 65 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(f) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 66 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(g) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 67 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(h) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 68 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(i) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 69 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(g) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 70 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(k) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 71 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively;
(l) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 8, 72 and 10, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 11, 12 and 13, respectively; and
(m) a monoclonal antibody or antigen-binding fragment thereof comprising antibody heavy chain variable region HCDR1-3 sequences as shown in SEQ ID NOs: 14, 15 and 16, respectively, and antibody light chain variable region LCDR1-3 sequences as shown in SEQ ID NOs: 17, 18 and 19, respectively
or a monoclonal antibody or antigen-binding fragment thereof that competes with the monoclonal antibody or antigen-binding fragment of any one of (a) to (m).

### Claim 4 (depends on 1)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 1, wherein the monoclonal antibody is a recombinant antibody.

### Claim 5 (depends on 4)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 4, wherein the monoclonal antibody is selected from the group consisting of a murine antibody, a chimeric antibody, and a recombinant humanized antibody, or an antigen-binding fragment thereof.

### Claim 6 (depends on 5)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 5, wherein the monoclonal antibody is the humanized antibody and the framework (FR) sequences of the light chain and the heavy chain variable regions of the humanized antibody are derived from a human germline light chain and heavy chain, respectively, or a mutant sequence thereof.

### Claim 7 (depends on 6)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 6, wherein the humanized antibody comprises a heavy chain variable region as shown in SEQ ID NO: 44 or 31 or a variant thereof; wherein the variant has 1-10 amino acid mutations in the heavy chain variable region sequence of SEQ ID NO: 44 or 31, respectively.

### Claim 8 (depends on 7)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 7, wherein the variant has 1-10 amino acid back-mutations in the FR region of the heavy chain variable region sequence of SEQ ID NO: 44 or 31, and the back-mutation is selected from the group consisting of D89E, R98T, G49A, M48I, M70L, R38K and V68A back-mutations in the heavy chain variable region sequence of SEQ ID NO: 44 or selected from Q3K or R87K back-mutation in the heavy chain variable region sequence of SEQ ID NO: 31.

### Claim 9 (depends on 8)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 8, wherein the humanized antibody comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 45-50 or comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 34-35.

### Claim 10 (depends on 6)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 6, wherein the humanized antibody comprises a light chain variable region as shown in SEQ ID NO: 21 or 32 or a variant thereof; wherein the variant has 1-10 amino acid mutations in the light chain variable region sequence of SEQ ID NO: 21 or 32.

### Claim 11 (depends on 10)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 10, wherein the variant has 1-10 amino acid back-mutations in the FR region of the light chain variable region sequence of SEQ ID NO: 21 or 32, and the back-mutation is the A43 S back-mutation in the light chain variable region sequence of SEQ ID NO: 21 or the Q3K, I48V, K45Q, A43S or T85S back-mutation in the flight chain variable region sequence of SEQ ID NO: 32.

### Claim 12 (depends on 11)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 11, wherein the humanized antibody comprises a light chain variable region sequence of SEQ ID NO: 30 or comprises a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 37-40.

### Claim 13 (depends on 6)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 6, wherein the humanized antibody comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 44-50 and a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 29-30; or comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 22-28 and a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 29-30; or comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 33-35 and a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 36-40.

### Claim 14 (depends on 6)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 6, wherein the humanized antibody comprises a heavy chain variable region sequence selected from the group consisting of SEQ ID NOs: 51-61 and a light chain variable region sequence selected from the group consisting of SEQ ID NOs: 29-30.

### Claim 15 (depends on 1)

The TIM-3 antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody is a full-length antibody, comprising a human antibody constant region comprising a human heavy chain constant region sequence as shown in SEQ ID NO: 41 and comprising a human light chain constant region sequence as shown in SEQ ID NO: 42.

### Claim at position 16

16-17. (canceled)

### Claim 18 (depends on 1)

A composition comprising a therapeutically effective amount of the TIM-3 antibody or antigen-binging fragment thereof according to claim 1 and one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 19 (depends on 1)

A nucleic acid molecule, encoding the antibody or antigen-binding fragment thereof according to claim 1.

### Claim 20 (depends on 19)

A recombinant vector, comprising the nucleic acid molecule according to claim 19.

### Claim 21 (depends on 20)

A host cell transformed with the recombinant vector according to claim 20, wherein the host cell is selected from the group consisting of prokaryotic cells and eukaryotic cells.

### Claim 22 (depends on 21)

A method comprising cultivating the host cell according to claim 21 in a culture to form and accumulate the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof from the culture.

### Claim at position 22

23-25. (canceled)

### Claim 26 (depends on 1)

A method for diagnosing a disease related to human TIM-3 positive cells, wherein the method comprises detecting or measuring human TIM-3 or TIM-3 positive cells by using the antibody or antigen-binding fragment thereof according to claim 1.

### Claim at position 24

27-28. (canceled)

### Claim 29 (depends on 18)

A method for treating a disease related to human TIM-3 positive cells in a subject in need thereof, comprising administering to the subject the pharmaceutical composition according to claim 18.

### Claim 30

(canceled)
